AI will change MedTech twice. First, it will change the economics of how companies sell. Then, it will change the logic by which customers decide what to buy.
A Medtech sales leader can see the problem in a territory plan before it shows up in a productivity report.
A few years ago, most of the opportunity might have sat inside ten large hospitals. Today, much of that same procedure volume is spread across hospitals, ASCs, and office-based sites. The market has not disappeared. It has become more expensive to cover.
Why Smaller Accounts Cost the Same to Serve
The reason is simple: commercial effort does not shrink in proportion to account size.
A surgeon performing 40 relevant cases a year at an ASC may still require product training, contracting, inventory coordination, case support, and regular engagement. The account can generate a fraction of a large hospital's revenue while demanding a meaningful share of a representative’s time. Replicate that across dozens of sites and territory productivity starts to erode.
This is the economic consequence of site-of-care fragmentation that deserves more attention. Revenue can fragment faster than the cost of serving it.
AI as Capacity, Not a Replacement
Medtech has historically solved coverage problems by adding people. More opportunity meant more territories, representatives, and managers. That logic worked when procedure volume was concentrated enough to support it. It becomes increasingly difficult when customers are distributed across more locations, physician access is harder, pricing remains under pressure, and SG&A cannot expand indefinitely.
AI matters here because it introduces another source of commercial capacity.
Not an autonomous sales force, but a different allocation of work.
A representative should not need to spend hours assembling basic account context, deciding which opportunities deserve attention, reconstructing prior interactions, or preparing routine follow-up.
Machines and AI systems can absorb more of that research, synthesis, prioritization, and coordination. Platforms like RepSignal are built to absorb exactly this kind of research and synthesis, giving reps ready-made account context instead of hours of manual reconstruction. Experienced people can spend a greater share of their time where judgment and relationships matter: solving clinical problems, navigating complex accounts, and developing strategic customers.
The implications are even more important at the edge of the territory. Some smaller sites will never justify the same field coverage as a major health system. Historically, the choice was often to cover them expensively or inconsistently. Better intelligence and digital engagement create more options between those extremes.
The salesperson does not disappear. The assumption that every additional dollar of reachable opportunity requires a proportional increase in human coverage does not.
That raises a harder question:
If AI existed when we designed our commercial model, would we have designed the model we have today?
Probably not.
But reaching more accounts is only useful if the organization can tell which ones deserve attention. That is where the next constraint appears.
Don't miss the next post in this four-part series. Follow S2N Health on LinkedIn to catch it as soon as it goes live.